OneSource Q3FY26 Results; Transitional Quarter – Revenue Deferred Pending Customer Approvals for Semaglutide in Canada

▴ OneSource Q3FY26 Results
OneSource Speciality Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter ended December 31, 2025 (Q3FY26).

 Q3FY26 Performance Highlights

  • Revenues at ₹2,903 million, down 26% YoY, impacted by delayed semaglutide approvals in Canada
  • EBITDA at ₹173 million, down 88% YoY, due to lower revenue in the quarter and largely fixed cost base
  • Adjusted PAT stood at (₹472) million with adjusted EPS of (₹4.1)
  • Effective interest rate (EIR) below 9%, 200bps lower YoY

 

FY28 Guidance Reaffirmation

  • ₹400 million in organic revenue and ₹500 million including recently proposed acquisition, with a ~40% EBITDA margin outlook, subject to shareholder approvals
  • Organic business targeting ROCE1 above 50% and Net-to-EBITDA below 1.5x
  1. Goodwill and Scheme Intangibles arising from the business combination is excluded from the ROCE calculation as it is not reflective of operating performance in the absence of common control. Capital employed excludes new capital investment in progress.


Bangalore, India, January 23, 2026 -
 OneSource Speciality Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter ended December  31, 2025 (Q3FY26).

Financial Highlights (In ₹ million)

Particulars

Q3FY26

Q2FY26

Q3FY25

YoY

Revenues

2,903

3,758

3,926

(26%)

EBITDA

173

1,065

1,419

(88%)

EBITDA %

6%

28%

36%

    (3,018 bps)

Adjusted PAT1

(472)

449

672

-

Adjusted EPS1

(4.1)

3.9

6.2

-

 

Note: Adjusted PAT and Adjusted EPS excludes exceptional items (Q3FY26: ₹71m, Q2FY26: Nil, Q3FY25: ₹1,005m) and scheme related intangible amortisation (Q3FY26: ₹344m, Q2FY26: ₹344m, Q3FY25: ₹355m)

 

Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, “As previously anticipated, this has been a subdued quarter due to delays in customer approvals in Canada that have prolonged the transition from the MSA to the CSA phase. The inherent demand, however, remains intact with order book continuing to trend upwards. In our nascent biologics segment, we continue to witness strong interest, with another global biosimilar player onboarded and the funnel at a historic high.”

 

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026